TMO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TMO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Thermo Fisher Scientific's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $48,972 Mil. Thermo Fisher Scientific's Total Assets for the quarter that ended in Sep. 2024 was $100,364 Mil. Therefore, Thermo Fisher Scientific's Equity to Asset Ratio for the quarter that ended in Sep. 2024 was 0.49.
The historical rank and industry rank for Thermo Fisher Scientific's Equity-to-Asset or its related term are showing as below:
During the past 13 years, the highest Equity to Asset Ratio of Thermo Fisher Scientific was 0.54. The lowest was 0.43. And the median was 0.48.
The historical data trend for Thermo Fisher Scientific's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thermo Fisher Scientific Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Equity-to-Asset | Get a 7-Day Free Trial | 0.51 | 0.50 | 0.43 | 0.45 | 0.47 |
Thermo Fisher Scientific Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Equity-to-Asset | Get a 7-Day Free Trial | 0.47 | 0.47 | 0.47 | 0.48 | 0.49 |
For the Diagnostics & Research subindustry, Thermo Fisher Scientific's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Thermo Fisher Scientific's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Thermo Fisher Scientific's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Thermo Fisher Scientific's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Equity to Asset (A: Dec. 2023 ) | = | Total Stockholders Equity | / | Total Assets |
= | 46735 | / | 98726 | |
= | 0.47 |
Thermo Fisher Scientific's Equity to Asset Ratio for the quarter that ended in Sep. 2024 is calculated as
Equity to Asset (Q: Sep. 2024 ) | = | Total Stockholders Equity | / | Total Assets |
= | 48972 | / | 100364 | |
= | 0.49 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thermo Fisher Scientific (NYSE:TMO) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of Thermo Fisher Scientific's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Marc N Casper | officer: Senior Vice President | C/O THERMO FISHER SCIENTIFIC, 168 THIRD AVENUE, WALTHAM MA 02451 |
Lisa P. Britt | officer: Sr. VP and Chief HR Officer | 168 THIRD AVENUE, WALTHAM MA 02451 |
Joseph R. Holmes | officer: VP & Chief Accounting Officer | 168 THIRD AVENUE, WALTHAM MA 02451 |
Gianluca Pettiti | officer: Executive Vice President | C/O BUTTERFLY NETWORK, INC., 530 OLD WHITFIELD STREET, GUILFORD CT 06437 |
Michael A Boxer | officer: Sr. VP and Gen. Counsel | 168 THIRD AVENUE, WALTHAM MA 02451 |
Michel Lagarde | officer: Senior Vice President | 450 LEXINGTON AVE., 31ST FLOOR, NEW YORK NY 10017 |
Stephen Williamson | officer: Sr. VP and CFO | 81 WYMAN STREET, WALTHAM MA 02451 |
Debora L Spar | director | C/O GOLDMAN, SACHS & CO., 200 WEST STREET, NEW YORK NY 10282 |
Jennifer M Johnson | director | C/O FRANKLIN RESOURCES, INC., ONE FRANKLIN PARKWAY, SAN MATEO CA 94403-1906 |
Jim P Manzi | director | 81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454 |
Ruby R Chandy | director | 630 DUNDEE ROAD, SUITE 400, NORTHBROOK IL 60062 |
Mark P Stevenson | officer: Executive Vice President | 850 LINCOLN CENTRE DRIVE, FOSTER CITY CA 94404 |
R. Alexandra Keith | director | ONE PROCTER & GAMBLE PLAZA, CINCINNATI OH 45202 |
Peter E Hornstra | officer: Chief Accounting Officer | 81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454 |
Syed A. Jafry | officer: Sr. Vice President | 345 E. MAIN STREET, WARSAW IN 46580 |
From GuruFocus
By GuruFocus Research • 09-17-2024
By Business Wire • 07-11-2024
By Business Wire • 05-28-2024
By GuruFocus Research • 07-25-2024
By Business Wire • 05-22-2024
By GuruFocus Research • 07-30-2024
By GuruFocus Research • 05-28-2024
By GuruFocus Research • 08-20-2024
By GuruFocus Research • 07-23-2024
By Business Wire • 07-02-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.